MacroGenics Inc
NASDAQ:MGNX

Watchlist Manager
MacroGenics Inc Logo
MacroGenics Inc
NASDAQ:MGNX
Watchlist
Price: 1.57 USD -2.48% Market Closed
Market Cap: 99.3m USD

Operating Margin
MacroGenics Inc

-60.6%
Current
-124%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-60.6%
=
Operating Profit
-77.3m
/
Revenue
127.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
MacroGenics Inc
NASDAQ:MGNX
99.3m USD
-61%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
393.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.7B AUD
26%
NL
argenx SE
XBRU:ARGX
44.5B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD
8%
No Stocks Found

MacroGenics Inc
Glance View

Market Cap
99.3m USD
Industry
Biotechnology

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

MGNX Intrinsic Value
3.47 USD
Undervaluation 55%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-60.6%
=
Operating Profit
-77.3m
/
Revenue
127.6m
What is the Operating Margin of MacroGenics Inc?

Based on MacroGenics Inc's most recent financial statements, the company has Operating Margin of -60.6%.

Back to Top